Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-hypopharynx”
RecruitingNCT07088354 ↗
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
RecruitingNCT06831357 ↗
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
👨⚕️ Jinming Yu, Dr., Shandong Cancer Hospital and Institute📍 1 site📅 Started Jan 2025View details ↗
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Enrolling by InvitationNCT06763640 ↗
Prognostic Value of TIL in Nasopharyngeal Carcinoma
CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
👨⚕️ Yunpeng Zhao, doctor, The Second Qilu Hospital of Shandong University📍 1 site📅 Started Dec 2024View details ↗
Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
👨⚕️ Zhihao Lu, MD, Peking University Cancer Hospital & Institute📍 1 site📅 Started Nov 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →